Aeon provides a 60-minute, full-body preventive health check-up that integrates full-body MRI scans, advanced blood biomarkers, and genetic insights into a single clinical workflow reviewed by board-certified physicians and radiologists. The platform uses AI for automated imaging analysis, cross-validation across modalities to reduce false positives, and predictive modelling to produce personalized risk profiles covering over 500 conditions. Since launching in 2024, Aeon has detected early-stage cancers, aneurysms, Alzheimer’s and other conditions, including a case of previously undiagnosed kidney cancer that enabled life-saving surgery. The company reports a 0% false positive rate in clinical-grade follow-ups to date, which it cites as a key differentiator against overdiagnosis. Aeon has secured reimbursement-eligible status with Swiss insurers and has signed deals with Switzerland’s largest providers, including KPT, to make the checks more accessible. The team is led by CEO Tim Seithe and CPO Samuel Frey, with scientific advisor Dr. Andreas Lemke; planned next steps include geographic expansion and scaling its clinical network.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2025